Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters








Year range
1.
AJM-Alexandria Journal of Medicine. 2013; 49 (4): 355-362
in English | IMEMR | ID: emr-145389

ABSTRACT

Many rheumatologic manifestations have been associated with Hepatitis C virus [HCV] infection including; arthralgia, myalgia, fatigue, fibromyalgia, vasculitis, and sicca syndrome. The relationship between emergence and persistence of intrahepatic or circulating B cell clonotypes and HCV infection is still unknown. However accumulating evidences indicate that certain chemokines play a critical role in providing the appropriate environment for activation and expansion of naive lymphocytes, one of these chemokines is B cell-attracting chemokine-13 [CXCL13]. CXCL13 is a major regulator of B-cell trafficking. This study evaluates circulating levels of CXCL13 protein in chronically HCV-infected Egyptian patients compared with healthy controls and its association with articular synovial hypertrophy. Rheumatic manifestations were present in 85% of patients; included fatigue [20%], arthralgia [the commonest manifestation] [65%], fibromyalgia [22%], myalgia [37%], Rayunad's phenomenon [10%], peripheral neuropathy and arthritis [2.5%], and tendenitis [7.5]. Cryoglobulins recorded in this study were of type II and III mixed cryoglobulins [MC] positive in 25% all of which showed positive rheumatoid factor [RF]. Significant low levels of C3 and C4 were reported in the patient group. CXCL13 serum levels were significantly high in the patient group especially in the MC positive group compared to controls. The highest levels of CXCL13 were significantly associated with rheumatologic manifestations with or without mixed cryoglobulinemia and significantly associated with articular synovial hypertrophy


Subject(s)
Humans , Female , Male , Arthralgia/blood , /blood , Synovial Membrane/pathology , Hospitals, University
2.
Rev. salud pública ; 12(4): 669-681, ago. 2010. tab
Article in Spanish | LILACS | ID: lil-574939

ABSTRACT

Objetivo Determinar las concentraciones de aluminio en suero de pacientes con terapia de reemplazo renal crónico con hemodiálisis y las concentraciones en agua de redes de distribución y diálisis en dos unidades renales en Bogotá. Material y Métodos Estudio descriptivo en 63 pacientes en hemodiálisis y 20 individuos sanos. Las concentraciones de aluminio se determinaron por espectrofotometría de absorción atómica horno de grafito con corrección de lámpara de deuterio. Resultados El promedio de las concentraciones de aluminio en suero de los pacientes fue de 26,5 µg/L (11,2 a 49,2 µg/L, DE=8,03), en individuos sanos de 8,05 µg/L (menor al Límite de Detección a 17,2 µg/L, DE=4,31), en agua de diálisis fue menor a 2 µg/L y en agua de las redes de distribución menor a 200 µg/L. Conclusiones Las concentraciones de aluminio en el agua de la red de distribución y diálisis estudiadas se encontraron por debajo de los valores establecidos internacionalmente indicando un adecuado tratamiento de las mismas. Igualmente las concentraciones de aluminio pre-HD y post-HD observadas en los pacientes se encontraron por debajo de las reportadas en la literatura. El consumo de hidróxido de aluminio aumenta significativamente la concentración de aluminio en suero. Variables como edad, género, estado civil y situación laboral no son factores de riesgo que alteren significativamente las concentraciones de aluminio en suero.


Objective Determining aluminium concentrations in the serum of patients undergoing chronic renal replacement therapy with haemodialysis and concentration in distribution network water and dialysis in two renal units in Bogotá. Material and Methods This was a descriptive study of 63 haemodialysed patients and 20 healthy subjects. Aluminium concentration was determined in water and serum using graphite furnace atomic absorption spectrometry with deuterium lamp background corrector. Results Average aluminium concentration was 26.5 µg/L in patients (ranging from 11.2 to 49.2 µg/L; 8.03 standard deviation) and 8.05 µg/L in healthy individuals (ranging from undetectable to 17.2 µg/L; 4.31 standard deviation). Aluminium concentration in dialysis water and distribution network water was below 2 µg/L and 200 µg/L, respectively. Conclusions Aluminium concentration in water and serum in this study was below international standard values, thereby indicating appropriate treatment. Additionally, aluminium concentration in pre-HD and post-HD sera was below that reported previously. Aluminium hydroxide uptake increases aluminium concentration in serum. Personal situation regarding age, gender, civil and work status were not risk factors determining aluminium concentrations in serum.


Subject(s)
Adult , Aged , Female , Humans , Male , Middle Aged , Young Adult , Aluminum/blood , Hemodialysis Solutions/analysis , Kidney Failure, Chronic/therapy , Renal Dialysis , Aluminum Hydroxide/pharmacokinetics , Arthralgia/blood , Arthralgia/complications , Colombia , Cross-Sectional Studies , Cooking and Eating Utensils/statistics & numerical data , Habits , Kidney Failure, Chronic/blood , Kidney Failure, Chronic/complications , Maximum Allowable Concentration , Memory Disorders/blood , Memory Disorders/complications , Movement Disorders/blood , Movement Disorders/complications , Sampling Studies , Spectrophotometry, Atomic , Speech Disorders/blood , Speech Disorders/complications , Water/analysis
SELECTION OF CITATIONS
SEARCH DETAIL